54 new drugs will be approved in 2014, the most in the past 10 years

Source: bioprospecting July 22, 2014 although the market in April this year was affected by the monetary tightening policy of chairman of the Federal Reserve, the stock market fell all the way, but pharmaceutical and biotechnology stocks are still very healthy If anyone questions that, look at the list of new drugs approved this year So far, 25 new drugs have obtained the green channel of FDA in the United States Analysts expect this year to break the record of 43 new drugs approved in 2013, and become the year with the most new drugs approved in the past 10 years At present, the field of biotechnology is in a booming situation (see the table below) However, interestingly, there is no heavyweight drug among the new drugs approved in 2014, and the largest drug is otezla, PDE4 inhibitor of celgene company Otezla, which was used to treat psoriatic arthritis in March this year, was approved by FDA In the next five years, it is estimated that its contribution to sales is only $92.7 million Even so, some doubt whether its effectiveness matches its expensive price In fact, in this year's biomedical market, PD-1 antibody oncology drug and abbvie and Gillette's hepatitis C drug market are two attractive basic themes Since the approval of sovaldi last year, the hepatitis C drug has swept the list of major drug sales revenue At the same time, tumor immune drugs are also in the golden age, Merck used to treat melanoma drug pembrolizumab will be approved on October 28 Nivolumab, a new antibody drug of Bristol Myers Squibb, was approved this year It is expected to become a major breakthrough in the field of tumor immunotherapy in the future when it is used in the treatment of melanoma, renal cell carcinoma and non-small cell lung cancer Nivolumab has a sustained tumor response rate of 20% - 30% to a variety of cancers The new drug breaks the 10% - 15% limit of sustained tumor response rate, which has been hindering the development of cancer immunotherapy for the past 30 years.